ANTIPARKINSONIAN DRUGS
TOP 10 MCQ
1. Given below are two statements [GPAT-2023 SHIFT-II]
Statement I: Levodopa is metabolized peripherally but capable of crossing Blood Brain Barrier, thus a best drug in treating Parkinsonism
Statement II: Carbidopa crosses Blood Brain Barrier, thus a best combination for protecting levodopa in CNS
In light of the above statements, choose the CORRECT answer from the options given below
(a) Both Statement I and Statement II are true
(b) Both Statement I and Statement II are false
(c) Statement I is true but Statement II is false
(d) Statement I is false but Statement II is true
2. Which of the following is/are NOT TRUE about Parkinson’s disease [GPAT-2022]
[A] Parkinson’s disease is caused by the degeneration of the substantia nigra in the midbrain
[B] Parkinson’s disease is caused by the degenerative loss of nigrostriatal dopaminergic neurons
[C] Bradykinesia, rigidity and tremor are the main symptoms in Parkinson’s disease
[D] Parkinson’s disease is caused by the degenerative loss of nigrostriatal cholinergic neurons
Choose the correct answer from the options given below
(a) A, B and D only
(b) A, B and C only
(c) C only
(d) D only
3. Regarding Bromocriptine, which of the following statement is TRUE [GPAT-2022]
[A] It is a relatively selective dopamine Dâ‚‚ agonist with prominent action on pituitary lactotrophs (inhibit prolactin release)
[B] In striatum (antiparkinsonian)
[C] In CTZ (antiemetic)
[D] As an adjunctive treatment for type 2 DM
Choose the correct answer from the options given below
(a) A, B and D only
(b) A, B and C only
(c) B and D only
(d) A and B only
4. Amantadine is helpful in Parkinson’s disease because [GPAT-2017]
(a) It liberates dopamine from nerve endings
(b) It decreases cholinergic activity
(c) It is metabolized into dopamine
(d) It increases adrenergic activity
5. In Parkinson’s disease, there is a predominant loss of dopaminergic neurons in the [GPAT-2016]
(a) Substantia nigra
(b) Cerebellar cortex
(c) Cerebral cortex
(d) Locus coeruleus
6. Choose the correct pair of the neurodegenerative disorders from those given below [GPAT-2011]
(a) Parkinson’s disease and Alzheimer’s disease
(b) Schizophrenia and Mania
(c) Alzheimer’s disease and Schizophrenia
(d) Parkinson’s disease and Autism
7. The effects observed following systemic administration of Levodopa in the treatment of Parkinsonism has been attributed to its catabolism to Dopamine. Carbidopa can markedly increase the proportion of Levodopa that crosses the blood brain barrier by [GPAT-2010]
(a) Increasing penetration of Levodopa through BBB by complexation with it
(b) Decreasing peripheral metabolism of Levodopa
(c) Decreasing metabolism of Levodopa in the CNS
(d) Decreasing clearance of Levodopa from the CNS
8. Carbidopa is used because [GATE-2003]
(a) It crosses blood brain barrier
(b) It inhibits aromatic L-amino acid decarboxylase
(c) It inhibits MAO type A
(d) It inhibits MAO type B
9. Select the specific unwanted effect of L-DOPA [GATE-2003]
(a) Dementia
(b) Hypertension
(c) Dyskinesia
(d) Excitotoxicity
10. A patient showing muscle rigidity, bradykinesia, tremors and postural instability was administered levodopa. Which of the properties of levodopa is NOT TRUE [GATE-2004]
(a) Levo-dopa is preferred over dopamine because it can cross the blood brain barrier
(b) Levo-dopa is the levorotatory stereoisomer of 3,4-dihydroxy phenylalanine
(c) Levo-dopa gets decarboxylated in the brain to dopamine
(d) Levo-dopa is administered because of its strong antagonistic action on dopamine receptors
ANSWER KEY
| 1-c | 2-d | 3-a | 4-a | 5-a | 6-a | 7-b | 8-b | 9-c | 10-d |
|
|
|
